Study of the Clinical Benefits of Different Formulations of Amphotericin B

Qianfoshan Hospital

Status: Active, not recruiting

Conditions: Efficacy; Safety

Study type: Observational

Funder types: Other

Identifiers

NCT06123832

LCYX-YR-20230102

Details and patient eligibility

About

This project intends to carry out a multi-center retrospective observational real-world study to understand the current status of amphotericin B use by formulation type, compare the differences in safety and efficacy of each formulation in domestic clinical application, provide real-world evidence for clinical drug selection, and provide evidence-based evidence in support of rational clinical drug use.

Full description

The researchers selected patients with amphotericin B use records discharged from five tertiary hospitals across the country from January 1, 2020 to the present, extracted data according to the inclusion and exclusion criteria, and divided them into experimental and control groups, in order to understand the current status of amphotericin B use in each preparation type, compare the differences in the safety and efficacy of the various preparations in the domestic clinical application, and provide real-world evidence of the choice of clinical medication.

Enrollment: 184 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients discharged from January 1, 2020 to the present;
2. Patients with a record of amphotericin B use.

Exclusion criteria

1.Key information missing from patient studies.

Trial design

184 participants in 2 patient groups

Experimental Group

Description:

Liposomal Amphotericin B for Injection (Ampicillin®)

Control Group

Description:

Liposome of Amphotericin B for Injection (Fungoxone®), Cholesteryl Sulfate Complex of Amphotericin B for Injection (Amphotericin®), Amphotericin B for Injection